GTx, Inc. (NASDAQ:GTXI) saw unusually-strong trading volume on Wednesday . Approximately 16,549 shares traded hands during mid-day trading, a decline of 98% from the previous session’s volume of 742,375 shares.The stock last traded at $1.74 and had previously closed at $1.88.

A number of research analysts recently weighed in on GTXI shares. Zacks Investment Research raised shares of GTX from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Tuesday. BidaskClub raised shares of GTX from a “hold” rating to a “buy” rating in a research note on Saturday, September 1st. Stifel Nicolaus lowered shares of GTX from a “buy” rating to a “hold” rating in a research note on Friday, September 21st. ValuEngine lowered shares of GTX from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Finally, Robert W. Baird lowered shares of GTX from an “outperform” rating to a “neutral” rating and set a $17.00 price target on the stock. in a research note on Friday, September 21st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.25.

The company has a market cap of $37.75 million, a price-to-earnings ratio of -1.07 and a beta of 1.67.

GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.43). On average, analysts forecast that GTx, Inc. will post -1.62 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp raised its holdings in GTX by 222.4% in the 2nd quarter. Northern Trust Corp now owns 60,296 shares of the biopharmaceutical company’s stock valued at $923,000 after acquiring an additional 41,591 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in GTX by 31.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,943 shares of the biopharmaceutical company’s stock valued at $474,000 after acquiring an additional 7,473 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in GTX by 57.6% in the 2nd quarter. Point72 Asset Management L.P. now owns 170,250 shares of the biopharmaceutical company’s stock valued at $2,607,000 after acquiring an additional 62,250 shares during the last quarter. Renaissance Technologies LLC raised its holdings in GTX by 4.8% in the 2nd quarter. Renaissance Technologies LLC now owns 76,695 shares of the biopharmaceutical company’s stock valued at $1,174,000 after acquiring an additional 3,500 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in GTX in the 2nd quarter valued at about $296,000. Institutional investors own 28.38% of the company’s stock.

About GTX (NASDAQ:GTXI)

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

See Also: What is the NASDAQ?

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.